Lentinan is a purified beta-glucan compound extracted from the shiitake mushroom (Lentinula edodes). It is not a food product. It is a specific, isolated molecule made mostly of long chains called (1-3)-beta-D-glucan, pulled from the mushroom’s fruiting body or mycelium and refined into a pharmaceutical-grade injectable drug. In Japan, that purified injectable form is approved as an add-on treatment used alongside standard chemotherapy for certain cancers, most notably gastric (stomach) cancer.
Lentinan is different from the shiitake powder, capsules, or extracts sold as dietary supplements in the United States. That distinction is the most important thing to understand about this compound, and it comes up throughout this guide.
The Most Important Caution, Stated Upfront
Nothing in this article is medical advice, and nothing here should be used to start, stop, or change any cancer treatment. Lentinan’s approval in Japan applies to a specific injectable pharmaceutical product given by a clinician alongside chemotherapy. It does not apply to shiitake mushrooms eaten as food or to shiitake supplements taken by mouth. A person considering any complementary approach during cancer treatment should talk with their oncology team first, since some immune-stimulating compounds can interact with chemotherapy, radiation, or immunosuppressive medications.
Quick Facts Checklist
- Lentinan is a purified 1,3-beta-glucan isolated from shiitake mushrooms, not the whole mushroom itself.
- It is approved in Japan as a prescription adjunct to chemotherapy for certain cancers, given by injection.
- It has poor absorption when swallowed, which is why the approved pharmaceutical form is injected rather than taken as a pill.
- It is not approved by the U.S. Food and Drug Administration and is not part of standard cancer treatment in the United States, Europe, or most Western countries.
- Shiitake mushroom supplements sold in Western markets are dietary supplements, not the pharmaceutical-grade injectable drug, and they have not been tested the same way.
- Human clinical trial data comes mostly from Japan and China; independent replication in Western clinical settings is limited.
Lentinan vs. General Mushroom Beta-Glucans
Beta-glucans are a broad family of sugar-chain molecules found in the cell walls of many mushrooms, as well as in oats, barley, and yeast. Not all beta-glucans are the same. The way the sugar units link together, the length of the chain, and the molecule’s overall shape all affect how the body’s immune cells respond to it, if they respond at all. Our general guide to mushroom beta-glucans covers this variation in more depth.
Lentinan is one specific, well-characterized beta-glucan from shiitake. It sits in the same broad category as PSK (polysaccharide-K), the purified beta-glucan compound from turkey tail mushroom that is also an approved cancer adjunct therapy in Japan. Our turkey tail mushroom research page covers PSK’s similar regulatory story. Lentinan and PSK are both purified pharmaceutical extracts studied in cancer patients. Neither is the same thing as eating the whole mushroom or taking a general-purpose supplement capsule.
Japan’s Approval: What It Actually Covers
According to drug information compiled from Japanese clinical use, lentinan is approved in Japan as a pharmaceutical product, most often used as an adjuvant, meaning it is added on top of standard chemotherapy rather than used by itself. It is typically given by injection, often intraperitoneally or intravenously, because swallowed lentinan is poorly absorbed by the digestive system. This is a critical detail: the approval covers a specific injectable drug administered in a clinical setting under medical supervision, not an oral supplement a person could buy and take at home.
The approval also does not mean lentinan cures cancer or replaces chemotherapy, radiation, or surgery. It is authorized as a supportive addition to conventional treatment in specific cancer types and specific clinical protocols, decided by a treating physician.
Why That Approval Has Not Extended to Western Markets
Lentinan has not received approval from the FDA or equivalent regulators in Europe. A few factors explain this gap, based on how drug approval systems generally work:
- Most of the clinical trial data on lentinan comes from studies conducted in Japan and China, and Western regulators generally require trials that meet their own specific design, reporting, and replication standards before granting approval.
- The number of large, rigorously controlled trials published in English-language, peer-reviewed journals remains limited, which makes it harder for outside regulators and researchers to independently evaluate the evidence.
- Injectable biological response modifiers like lentinan require a manufacturer to pursue a full drug approval pathway in each country or region separately. That is a long, expensive process, and it has not been completed for lentinan in the United States.
- Because it is not approved as a drug in the U.S., shiitake-derived products here are regulated only as dietary supplements, which follow a very different, lighter set of rules than prescription drugs.
None of this means the Japanese research is invalid. It means the evidence has not yet cleared the specific regulatory bar that Western agencies require, and independent confirmation in Western clinical trial settings is limited.
What the Human Clinical Research Shows
Human clinical trials on lentinan, most conducted in Japan and China over several decades, have studied injectable lentinan combined with chemotherapy in cancers including gastric (stomach), colorectal, hepatocellular (liver), and pancreatic cancer. Some published trials and reviews report survival or quality-of-life improvements for patients receiving lentinan alongside chemotherapy compared with chemotherapy alone. Other reviews of the same body of literature describe the overall evidence of efficacy as limited or inconclusive, pointing to small trial sizes and inconsistent study design. Reported side effects at standard clinical dosages are generally mild, though rapid intravenous infusion has been linked to more serious reactions in some cases, including hypersensitivity responses.
Three limits matter here. First, this human evidence applies to the injectable pharmaceutical compound administered in supervised clinical settings, not to any oral supplement. Second, the research base is limited in size and concentrated in Japan and China, with limited independent replication elsewhere. Third, reviewers disagree on how strong the evidence actually is, which is itself a sign that firm conclusions are not yet warranted.
Preclinical and Mechanistic Research (Not Yet Proven in Humans)
A separate body of laboratory and animal research looks at how lentinan might work in the body. This research describes lentinan as a biological response modifier, meaning it does not appear to kill cancer cells directly the way chemotherapy drugs do. Instead, laboratory studies suggest it may stimulate parts of the immune system, including natural killer cell activity, T-helper cells, and signaling molecules like interferon and interleukins. Animal studies have also explored whether lentinan can improve the effectiveness of chemotherapy or trigger cancer cell death in lab models.
This mechanistic and animal research helps explain why scientists became interested in lentinan in the first place. But it is not the same as proof that lentinan treats cancer in people. Findings from a petri dish or a mouse study frequently do not hold up the same way in human clinical trials, and readers should not treat preclinical findings as an established human outcome.
Pharmaceutical Lentinan vs. Dietary Shiitake Supplements
This is the distinction that gets confused most often in casual conversation about shiitake mushrooms and cancer. The two products are not interchangeable:
- Pharmaceutical lentinan: A purified, standardized, injectable drug given by a clinician in specific approved settings, mainly in Japan and China, as an addition to chemotherapy.
- Dietary shiitake supplements: Capsules, powders, or extracts sold over the counter, taken orally, made from whole mushroom material with variable and generally low lentinan content that has not been standardized or clinically tested the way the pharmaceutical version has.
- Absorption: Pharmaceutical lentinan is injected specifically because swallowed lentinan is poorly absorbed. An oral supplement is working against that same absorption limitation.
- Regulatory status: The pharmaceutical version is an approved drug in Japan. The dietary supplement version is not a drug anywhere in Western markets and is not evaluated by the FDA for effectiveness before it reaches store shelves.
- Evidence base: Clinical trial data exists for the injectable pharmaceutical form. It does not exist in the same way for oral shiitake supplements marketed for cancer support.
A Simple Decision Path for Thinking About This Topic
- Are you asking about a shiitake supplement you can buy over the counter? The clinical research on lentinan does not apply to it in the same way, because it is a different product with different absorption and a different evidence base.
- Are you asking about lentinan as part of a cancer treatment plan? That is a conversation for an oncologist, since the approved use is a supervised injectable therapy layered onto conventional treatment, not a self-directed choice.
- Are you researching this out of general interest in mushroom bioactive compounds? Lentinan is a useful case study in how a compound can be rigorously studied and even approved in one country’s medical system while remaining unapproved elsewhere, largely due to differing regulatory evidence requirements.
- Are you trying to evaluate a claim you saw online? Check whether the claim is describing the injectable pharmaceutical compound or a retail supplement. Many misleading claims blur this line on purpose or by mistake.
Who Should Be Extra Cautious
- Anyone currently undergoing chemotherapy, radiation, or targeted cancer therapy should not add any mushroom-derived supplement without first checking with their oncology team, since immune-stimulating compounds can interact with treatment.
- People with autoimmune conditions should be cautious with immune-stimulating compounds generally and should discuss any mushroom supplement with their physician.
- People scheduled for surgery are often advised by their care team to stop immune-modulating supplements beforehand; this is a decision for the surgical and medical team, not a general rule to self-apply.
- People taking immunosuppressive medications, including after an organ transplant, should not use immune-stimulating mushroom compounds without medical guidance.
- People who have had allergic reactions to mushrooms, or who develop a rash after handling or eating shiitake (sometimes called shiitake flagellate dermatitis), should discuss any shiitake-derived product with a healthcare provider.
Evidence Limits
Readers should keep several limits in mind. Most clinical trial data on lentinan comes from Japan and China, and broader independent replication in Western clinical trial settings remains limited. The pharmaceutical evidence base does not transfer to oral dietary supplements, which have not been tested to the same standard. Mechanistic and animal research explains a possible biological pathway but is not proof of a human outcome. Finally, “approved in Japan” describes a specific regulatory decision for a specific injectable drug in a specific adjunct role. It is not the same as being a proven, stand-alone cancer treatment, and it does not extend to any product sold as a dietary supplement.
Frequently Asked Questions
Is lentinan the same thing as shiitake mushroom powder or extract?
No. Lentinan is a specific purified beta-glucan compound isolated from shiitake and manufactured into an injectable pharmaceutical product. Shiitake powders, capsules, and extracts sold as supplements contain whole mushroom material with variable, generally low amounts of lentinan and have not been through the same testing or approval process.
Can I get the same benefit from eating shiitake mushrooms or taking a shiitake supplement?
The clinical research behind lentinan’s approval in Japan used an injectable pharmaceutical form given in supervised medical settings. That research cannot be assumed to apply to eating shiitake mushrooms as food or taking an oral supplement, partly because swallowed lentinan is poorly absorbed by the digestive system.
Why is lentinan approved in Japan but not in the United States?
Different countries require different clinical trial evidence before approving a drug. Most lentinan research comes from Japan and China, and it has not yet cleared the specific evidence requirements of the FDA or European regulators, who generally look for large, independently replicated trials before approval decisions.
Should someone with cancer take a shiitake supplement instead of their prescribed treatment?
No one should stop, delay, or replace a prescribed cancer treatment with a dietary supplement. Any interest in mushroom-derived compounds like lentinan during cancer care should be discussed directly with the treating oncology team, who can weigh it against the specific treatment plan.
Educational Disclaimer
This article is for general educational purposes only. It is not medical advice and does not diagnose, treat, or cure any condition. It should not be used as a substitute for professional medical care. Anyone with questions about cancer treatment, dietary supplements, or interactions with medication should speak with a qualified healthcare provider. For background on how to weigh clinical evidence in mushroom research generally, see our guide to evidence hierarchy. For more on shiitake mushrooms generally, see our shiitake mushroom research and safety guide.